Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma.
about
The Saudi Initiative for Asthma.Long-term maintenance of pediatric asthma: focus on budesonide/formoterol inhalation aerosol.Systemic bioavailability of hydrofluoroalkane (HFA) formulations of fluticasone/salmeterol in healthy volunteers via pMDI alone and spacerβ2 adrenergic agonist attenuates house dust mite-induced allergic airway inflammation through dendritic cells.Pharmacogenomics of long-acting β2-agonists.Drug prescription pattern for asthma among nigerian doctors in general practice: A cross-sectional survey.The relationship between combination inhaled corticosteroid and long-acting β-agonist use and severe asthma exacerbations in a diverse population.The role of tiotropium in the management of asthma.Canadian Thoracic Society 2012 guideline update: diagnosis and management of asthma in preschoolers, children and adults.Asthma exacerbations . 4: Prevention.The Saudi initiative for asthma - 2012 update: Guidelines for the diagnosis and management of asthma in adults and childrenThe Saudi Initiative for Asthma - 2016 update: Guidelines for the diagnosis and management of asthma in adults and children.Section 1. EPR-3 versus GINA 2008 Guidelines - Asthma Control and Step 3 Care: Highlights of the Asthma Summit 2009: Beyond the Guidelines.Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trialPharmacotherapy of asthma: regular treatment or on demand?Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone.Effects of asthma treatment: the present and future.Use of long-acting beta-agonists and inhaled steroids in asthma: meta-analysis of observational studies.Retrospective comparison of early versus late treatment with fluticasone propionate/salmeterol after an asthma exacerbation.Increased Dose of Inhaled Corticosteroid versus Add-On Long-acting β-Agonist for Step-Up Therapy in Asthma.Are inhaled long-acting Beta-agonists (laba) really harmful in adult asthmatics?Clinical importance of the Step 3 choice in asthmaCombination therapy salmeterol/fluticasone versus doubling dose of fluticasone in children with asthma.The pharmacokinetics, safety, and tolerability of single, high-strength doses of fluticasone propionate and fluticasone propionate/salmeterol delivered via a novel multidose dry powder inhaler in adolescents and adults with persistent asthma.Randomized, double-blind trial evaluating the efficacy and safety of fluticasone propionate and fluticasone propionate/salmeterol delivered via multidose dry powder inhalers in patients with persistent asthma aged 12 years and older.Long-acting β2-agonists promote glucocorticoid-mediated repression of NF-κB by enhancing expression of the feedback regulator TNFAIP3.Addition of transdermal or inhaled long-acting Beta2-agonists in adult asthmatic patients treated with inhaled corticosteroids: switchover study from tulobuterol patch to salmeterol dry powder inhaler.Use and safety of long-acting β2-agonists for pediatric asthmaEvaluating the Impact and Benefits of Fluticasone Furoate/Vilanterol in Individuals with Asthma or COPD: A Mixed-Methods Analysis of Patient Experiences
P2860
Q33568644-1F2A5F79-8BB9-40E7-B355-3B0B6B6517E9Q33715425-B499633B-995F-4FAA-9145-05F4B07E5C4FQ33906322-712F4D44-D068-4B98-863B-5B4547A1F326Q34492011-A8CA1EEC-DB68-48C1-A27D-8B2728E98343Q35734012-9769A9A4-78CF-4471-8DBF-D4F14A00B2BBQ35919554-A8D97752-A095-4D8D-833B-45067C598133Q35923040-443FF0A0-DB99-4A78-BCCA-7290089978E5Q35937096-764634A5-36CE-4296-94F6-3A1EEFD7C687Q36027085-E5EA51A1-6676-45C7-8A3C-5A6C663F72BEQ36237953-F1715A8D-57C0-491C-9811-390EAFDEB61DQ36422663-B604E05E-2E5A-4C06-828A-F17F9ED9F12AQ36566081-50162391-A5FE-4454-8E00-25230D51B40BQ36834760-CCEB7E09-A805-41DE-A764-89C17B5AD8A7Q37209570-F666FC5F-6908-464B-97FA-6B944FFA0819Q37578103-6CADDEEF-6120-424B-80F7-95B47A142B9EQ37658668-2B8509DD-0EBB-49CB-95F5-5BC73A8DCFC0Q37755242-07C4A617-A7F7-49F7-B2D4-7740EA9EFB43Q37763188-9C1F3C60-11C1-49D9-8093-B84809068AC9Q39724263-DA99D545-3863-4CDC-95DD-7516E92941BFQ41256329-2E9181AF-033E-4897-A6AC-B8DD89A9D9E6Q41815672-2003A267-BB0D-4685-A415-14D553DB0E98Q42743778-B7EE5B79-61D4-4B8D-A48F-813A3DF8F6BDQ42973500-579148E9-3BB8-4485-AA7F-8034E6D63AA2Q47651886-6C2D0753-441D-41A8-A479-92AD1CD71393Q47858456-0C092302-7485-4E52-9208-9FF6216AE157Q48105513-7C270A44-FC4B-44BD-805E-2A9D672BD27EQ50697600-9425810A-A563-4F79-9E66-110AD2476E9BQ57821604-C97AE946-B929-4C93-8DD1-5768D0BE481FQ58784324-35CEA474-8020-40F6-8684-EE5996DC3ECC
P2860
Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Moderate dose inhaled corticos ...... teroids in symptomatic asthma.
@ast
Moderate dose inhaled corticos ...... teroids in symptomatic asthma.
@en
type
label
Moderate dose inhaled corticos ...... teroids in symptomatic asthma.
@ast
Moderate dose inhaled corticos ...... teroids in symptomatic asthma.
@en
prefLabel
Moderate dose inhaled corticos ...... teroids in symptomatic asthma.
@ast
Moderate dose inhaled corticos ...... teroids in symptomatic asthma.
@en
P2860
P356
P1433
P1476
Moderate dose inhaled corticos ...... steroids in symptomatic asthma
@en
P2860
P304
P356
10.1136/THX.2004.039180
P407
P577
2005-09-01T00:00:00Z